Novo Aims To Go Significantly Beyond With Latest Obesity Deal

 
• By Elizabeth Cairns
  
Generate a summary of this article
Listen to this article
Beta

Combination mechanisms, less frequent dosing and scalability are the goals of the collaboration.    

Team teamwork togetherness collaboration concept
• Source: Alamy

Novo Nordisk A/S, the most valuable company in Europe thanks to sales of its semaglutide-based metabolic drugs, has long had an eye to what happens when these springs run dry. The latest in the Danish group’s string of early-stage collaborations, aimed at securing potential new obesity therapies, is a $600m research tie-up with Metaphore Biotechnologies.

Key Takeaways

  • Novo Nordisk has struck an obesity drug discovery pact with Metaphore Biotechnologies with $600m

“We want to work with Metaphore, and [other] organizations which have a unique platform we don’t have, so that we...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

Test Roche Head Of Pharma Strategy Karsten Jung On Rebuilding The Portfolio

 
• By Jessica Merrill

The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Reed Miller

In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.

Article Without An Author Listed

Here is a short description.

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains